{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Detrusor+Overactivity&page=2", "query": { "condition": "Detrusor Overactivity", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Detrusor+Overactivity&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T16:28:18.435Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01557244", "title": "A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder, Neurogenic" ], "interventions": [ { "name": "Fesoterodine PR 4 mg", "type": "DRUG" }, { "name": "Fesoterodine PR 8 mg", "type": "DRUG" }, { "name": "Oxybutynin", "type": "DRUG" }, { "name": "Fesoterodine PR", "type": "DRUG" }, { "name": "Fesoterodine BIC 2 mg", "type": "DRUG" }, { "name": "Fesoterodine BIC 4 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 181, "start_date": "2012-07-02", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 18, "location_summary": "Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01557244" }, { "nct_id": "NCT03033355", "title": "Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis", "Lower Urinary Tract Symptoms", "Neurogenic Bladder", "Detrusor, Overactive", "Urge Incontinence" ], "interventions": [ { "name": "Intra-detrusor injection of Onabotulinumtoxin-A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2014-02", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03033355" }, { "nct_id": "NCT06212661", "title": "Migraine Medication Effects on Urinary Symptoms", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Overactive Bladder", "Bladder Pain Syndrome", "Migraine Disorders", "Overactive Bladder Syndrome", "Overactive Detrusor", "Migraine", "Interstitial Cystitis" ], "interventions": [ { "name": "Ubrogepant", "type": "DRUG" }, { "name": "Rimegepant", "type": "DRUG" }, { "name": "Atogepant", "type": "DRUG" }, { "name": "Eptinezumab", "type": "DRUG" }, { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Galcanezumab", "type": "DRUG" }, { "name": "Erenumab", "type": "DRUG" }, { "name": "Botulinum toxin A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2024-04-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06212661" }, { "nct_id": "NCT00373789", "title": "Refractory Urge Incontinence and Botox Injections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Incontinence", "Detrusor Overactivity", "Urinary Urgency", "Urge Urinary Incontinence" ], "interventions": [ { "name": "Botulinum Toxin A, bladder detrusor muscle injection", "type": "DRUG" }, { "name": "Vehicle saline as placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2006-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2011-01-11", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 8, "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00373789" }, { "nct_id": "NCT05491525", "title": "Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neurogenic Detrusor Overactivity" ], "interventions": [ { "name": "Vibegron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Urovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 71, "start_date": "2022-10-12", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05491525" }, { "nct_id": "NCT00224016", "title": "Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Detrusor Hyperreflexia" ], "interventions": [ { "name": "Oxybutynin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Watson Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "6 Years to 15 Years" }, "enrollment_count": 57, "start_date": "2004-12", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2012-02-09", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange County", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224016" }, { "nct_id": "NCT01852058", "title": "A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Incontinence" ], "interventions": [ { "name": "OnabotulinumtoxinA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 95, "start_date": "2014-01-11", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01852058" }, { "nct_id": "NCT00805779", "title": "Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Urinary Bladder, Overactive" ], "interventions": [ { "name": "MagPro R30", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "EMKinetics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-12", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805779" }, { "nct_id": "NCT01981954", "title": "A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurogenic Detrusor Overactivity", "Pediatric" ], "interventions": [ { "name": "Solifenacin succinate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Europe B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "4 Years", "sex": "ALL", "summary": "6 Months to 4 Years" }, "enrollment_count": 23, "start_date": "2013-09-25", "completion_date": "2015-12-18", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 1, "location_summary": "Tarrytown, New York", "locations": [ { "city": "Tarrytown", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01981954" }, { "nct_id": "NCT01661166", "title": "A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Fesoterodine", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "30 Years to 90 Years · Male only" }, "enrollment_count": 3, "start_date": "2012-01", "completion_date": "2013-04-15", "has_results": false, "last_update_posted_date": "2020-04-28", "last_synced_at": "2026-07-22T16:28:18.435Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661166" } ] }